An Aging-Related Gene Signature-Based Model for Risk Stratification and Prognosis Prediction in Breast Cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Sachs N, de Ligt J, Kopper O, et al. A living biobank of breast cancer organoids captures Disease heterogeneity. Cell. 2018;172(1–2):373–86.e10. doi:10.1016/j.cell.2017.11.010
   PubMed Web of Science ®Google Scholar
• Yeo SK, Guan JL. Breast cancer: multiple subtypes within a tumor? Trends Cancer. 2017;3(11):753–760. doi:10.1016/j.trecan.2017.09.001
   PubMed Web of Science ®Google Scholar
• Latha N, Rajan A, Nadhan R, et al. Gene expression signatures: a tool for analysis of breast cancer prognosis and therapy. Crit Rev Oncol Hematol. 2020;151:102964. doi:10.1016/j.critrevonc.2020.102964
   Web of Science ®Google Scholar
• Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. doi:10.1001/jama.2018.19323
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–80. doi:10.1016/S1470-2045(14)71116-7
   PubMed Web of Science ®Google Scholar
• Shavlakadze T, Morris M, Fang J, et al. Age-related gene expression signature in rats demonstrate early, late, and linear transcriptional changes from multiple tissues. Cell Rep. 2019;28(12):3263–73.e3. doi:10.1016/j.celrep.2019.08.043
   Web of Science ®Google Scholar
• Armanios M, de Cabo R, Mannick J, Partridge L, van Deursen J, Villeda S. Translational strategies in aging and age-related disease. Nat Med. 2015;21(12):1395–1399. doi:10.1038/nm.4004
   Web of Science ®Google Scholar
• Benayoun BA, Pollina EA, Singh PP, et al. Remodeling of epigenome and transcriptome landscapes with aging in mice reveals widespread induction of inflammatory responses. Genome Res. 2019;29(4):697–709. doi:10.1101/gr.240093.118
   Web of Science ®Google Scholar
• Smetana K Jr, Lacina L, Szabo P, Dvořánková B, Brož P, Šedo A. Ageing as an important risk factor for cancer. Anticancer Res. 2016;36(10):5009–5017. doi:10.21873/anticanres.11069
   PubMed Web of Science ®Google Scholar
• Yin D, Chen K. The essential mechanisms of aging: irreparable damage accumulation of biochemical side-reactions. Exp Gerontol. 2005;40(6):455–465. doi:10.1016/j.exger.2005.03.012
   PubMed Web of Science ®Google Scholar
• López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–1217. doi:10.1016/j.cell.2013.05.039
   PubMed Web of Science ®Google Scholar
• Calcinotto A, Kohli J, Zagato E, Pellegrini L, Demaria M, Alimonti A. Cellular senescence: aging, cancer, and injury. Physiol Rev. 2019;99(2):1047–1078. doi:10.1152/physrev.00020.2018
   PubMed Web of Science ®Google Scholar
• Mosteiro L, Pantoja C, Alcazar N, et al. Tissue damage and senescence provide critical signals for cellular reprogramming in vivo. Science. 2016;354(6315):. doi:10.1126/science.aaf4445
   PubMed Web of Science ®Google Scholar
• He S, Sharpless NE. Senescence in health and disease. Cell. 2017;169(6):1000–1011. doi:10.1016/j.cell.2017.05.015
   PubMed Web of Science ®Google Scholar
• Zhao L, Zhang Y, Gao Y, et al. JMJD3 promotes SAHF formation in senescent WI38 cells by triggering an interplay between demethylation and phosphorylation of RB protein. Cell Death Differ. 2015;22(10):1630–1640. doi:10.1038/cdd.2015.6
   Web of Science ®Google Scholar
• Lee S, Schmitt CA. The dynamic nature of senescence in cancer. Nat Cell Biol. 2019;21(1):94–101. doi:10.1038/s41556-018-0249-2
   PubMed Web of Science ®Google Scholar
• Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature. 2013;493(7432):338–345. doi:10.1038/nature11861
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Differ. 2018;25(3):486–541. doi:10.1038/s41418-017-0012-4
   PubMed Web of Science ®Google Scholar
• Yue T, Chen S, Zhu J, et al. The aging-related risk signature in colorectal cancer. Aging. 2021;13(5):7330–7349. doi:10.18632/aging.202589
   PubMedGoogle Scholar
• Xu Q, Chen Y. An aging-related gene signature-based model for risk stratification and prognosis prediction in lung adenocarcinoma. Front Cell Dev Biol. 2021;9:685379. doi:10.3389/fcell.2021.685379
   PubMed Web of Science ®Google Scholar
• Srivastava S, Gopal-Srivastava R. Biomarkers in cancer screening: a public health perspective. J Nutr. 2002;132(8 Suppl):2471s–5s. doi:10.1093/jn/132.8.2471S
   Web of Science ®Google Scholar
• Tang Y, Hu Y, Wang J, Zeng Z. A novel risk score based on a combined signature of 10 immune system genes to predict bladder cancer prognosis. Int Immunopharmacol. 2020;87:106851. doi:10.1016/j.intimp.2020.106851
   Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Hothorn T, Zeileis A. Generalized maximally selected statistics. Biometrics. 2008;64(4):1263–1269. doi:10.1111/j.1541-0420.2008.00995.x
   PubMed Web of Science ®Google Scholar
• Xu H, Wang G, Zhu L, Liu H, Li B. Eight immune-related genes predict survival outcomes and immune characteristics in breast cancer. Aging. 2020;12(16):16491–16513. doi:10.18632/aging.103753
   Google Scholar
• Baloni P, Dinalankara W, Earls JC, et al. Identifying personalized metabolic signatures in breast cancer. Metabolites. 2020;11(1):20. doi:10.3390/metabo11010020
   Web of Science ®Google Scholar
• Tan W, Liu M, Wang L, et al. Novel immune-related genes in the tumor microenvironment with prognostic value in breast cancer. BMC Cancer. 2021;21(1):126. doi:10.1186/s12885-021-07837-1
   Web of Science ®Google Scholar
• Zhu L, Tian Q, Jiang S, et al. A novel ferroptosis-related gene signature for Overall survival prediction in patients with breast cancer. Front Cell Dev Biol. 2021;9:670184. doi:10.3389/fcell.2021.670184
   Web of Science ®Google Scholar
• Wang D, Wei G, Ma J, et al. Identification of the prognostic value of ferroptosis-related gene signature in breast cancer patients. BMC Cancer. 2021;21(1):645. doi:10.1186/s12885-021-08341-2
   PubMed Web of Science ®Google Scholar
• Du JX, Chen C, Luo YH, et al. Establishment and validation of a novel autophagy-related gene signature for patients with breast cancer. Gene. 2020;762:144974. doi:10.1016/j.gene.2020.144974
   PubMed Web of Science ®Google Scholar
• Eberhardt K, Beleites C, Marthandan S, Matthäus C, Diekmann S, Popp J. Raman and infrared spectroscopy distinguishing replicative senescent from proliferating primary human fibroblast cells by detecting spectral differences mainly due to biomolecular alterations. Anal Chem. 2017;89(5):2937–2947. doi:10.1021/acs.analchem.6b04264
   Web of Science ®Google Scholar
• Cheng X, Geng F, Pan M, et al. Targeting DGAT1 ameliorates glioblastoma by increasing fat catabolism and oxidative stress. Cell Metab. 2020;32(2):229–42.e8. doi:10.1016/j.cmet.2020.06.002
   Web of Science ®Google Scholar
• Xia L, Wang Y, Cai S, Xu M. DGAT1 expression promotes ovarian cancer progression and is associated with poor prognosis. J Immunol Res. 2021;2021:6636791. doi:10.1155/2021/6636791
   Web of Science ®Google Scholar
• He P, Cheng S, Hu F, Ma Z, Xia Y. Up-regulation of DGAT1 in cancer tissues and tumor-infiltrating macrophages influenced survival of patients with gastric cancer. BMC Cancer. 2021;21(1):252. doi:10.1186/s12885-021-07976-5
   Web of Science ®Google Scholar
• Wilson MR, Zoubeidi A. Clusterin as a therapeutic target. Expert Opin Ther Targets. 2017;21(2):201–213. doi:10.1080/14728222.2017.1267142
   PubMed Web of Science ®Google Scholar
• Tian Y, Wang C, Chen S, Liu J, Fu Y, Luo Y. Extracellular Hsp90α and clusterin synergistically promote breast cancer epithelial-to-mesenchymal transition and metastasis via LRP1. J Cell Sci. 2019;132(15). doi:10.1242/jcs.228213
   Web of Science ®Google Scholar
• Wang Y, Brodsky AS, Xiong J, Lopresti ML, Yang D, Resnick MB. Stromal clusterin expression predicts therapeutic response to neoadjuvant chemotherapy in triple negative breast cancer. Clin Breast Cancer. 2018;18(3):e373–e379. doi:10.1016/j.clbc.2017.08.00
   Web of Science ®Google Scholar
• Cascón A, Robledo M. MAX and MYC: a heritable breakup. Cancer Res. 2012;72(13):3119–3124. doi:10.1158/0008-5472.CAN-11-3891
   Web of Science ®Google Scholar
• Zhang D, Zheng Y, Yang S, et al. Identification of a novel glycolysis-related gene signature for predicting breast cancer survival. Front Oncol. 2020;10:596087. doi:10.3389/fonc.2020.596087
   PubMed Web of Science ®Google Scholar
• Verret B, Cortes J, Bachelot T, Andre F, Arnedos M. Efficacy of PI3K inhibitors in advanced breast cancer. Ann Oncol. 2019;30(Suppl 10):x12–x20. doi:10.1093/annonc/mdz381
   PubMed Web of Science ®Google Scholar
• Narayan P, Prowell TM, Gao JJ, et al. FDA approval summary: alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer. Clin Cancer Res. 2021;27(7):1842–1849. doi:10.1158/1078-0432.CCR-20-3652
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhu M, Li J, et al. Overexpression of PSMC2 promotes the tumorigenesis and development of human breast cancer via regulating plasminogen activator urokinase (PLAU). Cell Death Dis. 2021;12(7):690. doi:10.1038/s41419-021-03960-w
   PubMed Web of Science ®Google Scholar
• Derenzini E, Mazzara S, Melle F, et al. A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma. Haematologica. 2020;106(9). doi:10.3324/haematol.2019.236455
   Web of Science ®Google Scholar
• Li L, Zhang ZT. Genetic association between NFKBIA and NFKB1 gene polymorphisms and the susceptibility to head and neck cancer: a meta-analysis. Dis Markers. 2019;2019:6523837. doi:10.1155/2019/6523837
   Web of Science ®Google Scholar
• Curran JE, Weinstein SR, Griffiths LR. Polymorphic variants of NFKB1 and its inhibitory protein NFKBIA, and their involvement in sporadic breast cancer. Cancer Lett. 2002;188(1–2):103–107. doi:10.1016/s0304-3835(02)00460-3
   Web of Science ®Google Scholar
• Sebestyen Z, Prinz I, Déchanet-Merville J, Silva-Santos B, Kuball J. Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies. Nat Rev Drug Discov. 2020;19(3):169–184. doi:10.1038/s41573-019-0038-z
   PubMed Web of Science ®Google Scholar